- Home
- PBR vs VRTX Comparison
PBR vs VRTX Comparison
Compare PBR & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBR
- VRTX
- Stock Information
- Founded
- PBR 1953
- VRTX 1989
- Country
- PBR Brazil
- VRTX United States
- Employees
- PBR N/A
- VRTX N/A
- Industry
- PBR Oil & Gas Production
- VRTX EDP Services
- Sector
- PBR Energy
- VRTX Technology
- Exchange
- PBR Nasdaq
- VRTX Nasdaq
- Market Cap
- PBR 81.6B
- VRTX 96.6B
- IPO Year
- PBR N/A
- VRTX 1991
- Fundamental
- Price
- PBR $11.96
- VRTX $414.98
- Analyst Decision
- PBR Strong Buy
- VRTX Buy
- Analyst Count
- PBR 3
- VRTX 25
- Target Price
- PBR $15.57
- VRTX $494.23
- AVG Volume (30 Days)
- PBR 22.4M
- VRTX 1.8M
- Earning Date
- PBR 11-06-2025
- VRTX 11-03-2025
- Dividend Yield
- PBR 14.09%
- VRTX N/A
- EPS Growth
- PBR N/A
- VRTX N/A
- EPS
- PBR 1.01
- VRTX 14.07
- Revenue
- PBR $85,533,373,883.00
- VRTX $11,418,800,000.00
- Revenue This Year
- PBR $524.26
- VRTX $10.92
- Revenue Next Year
- PBR $0.26
- VRTX $9.55
- P/E Ratio
- PBR $11.87
- VRTX $29.49
- Revenue Growth
- PBR N/A
- VRTX 10.46
- 52 Week Low
- PBR $11.03
- VRTX $362.50
- 52 Week High
- PBR $15.10
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- PBR 33.89
- VRTX 60.72
- Support Level
- PBR $12.08
- VRTX $400.74
- Resistance Level
- PBR $12.33
- VRTX $422.73
- Average True Range (ATR)
- PBR 0.29
- VRTX 9.33
- MACD
- PBR -0.11
- VRTX 4.30
- Stochastic Oscillator
- PBR 0.32
- VRTX 85.24
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2024 was 2.7 million barrels of oil equivalent a day (80% oil production), and reserves stood at 11.4 billion boe (85% oil). At end-2024, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.